Semaglutide
GLP-1 receptor agonist studied for glycemic and weight research.
Category · Fat LossMech 10/10
View ProductAll pathwaysStrong Emerging Strong Moderate Limited Limited Limited
Metabolic & endocrine signaling systems
Metabolic Optimization Research Pathway
Incretins, lipolysis, the GH axis.
This pathway explores compounds studied for appetite signaling, insulin response, lipolysis, energy expenditure, and body composition research.
System Overview
The biological system this pathway studies.
Body composition is regulated by hormonal signaling across incretin (GLP-1, GIP, glucagon), insulin, and growth-hormone axes, alongside central appetite circuits and peripheral lipid metabolism. This pathway studies peptide and peptide-analog compounds that interact with these receptors and pathways to influence appetite, glycemic control, energy expenditure, and fat oxidation in research and clinical settings.
Educational research context · not medical advice
Why This Pathway Matters
Body composition is governed by hormonal signaling, nutrient sensing, and energy balance.
This pathway examines how compounds interact with incretin receptors (GLP-1, GIP, glucagon), the growth hormone axis, and lipid metabolism. Researchers study how these signals influence appetite regulation, glycemic control, and fat oxidation in preclinical and clinical models.
Metabolic signaling
Incretin receptors and the GH/IGF-1 axis.
Insulin response
Glycemic control and nutrient partitioning research.
Energy balance
Appetite regulation, lipolysis, and energy expenditure.
Educational research context · not medical advice
Research Progression Model
3 biological phases · click to explore
1
Research Phase 1
Appetite & Glucose Signaling
Research focus
These incretin-based compounds are studied for GLP-1, GIP, and glucagon receptor signaling, appetite regulation, glycemic control, and body weight research.
Studied Compounds
Semaglutide
Strong clinicalOperates within the incretin and appetite regulation pathway, acting on GLP-1 receptor signaling in both peripheral and central nervous system sites.
Major clinical trials measured body-weight and metabolic outcomes at 68 weeksTirzepatide
Strong clinicalOperates within the dual incretin receptor pathway, integrating GIP and GLP-1 signaling for combined effects on glycemic regulation and energy balance.
Major clinical trials measured outcomes at 72 weeksRetatrutide
Emerging clinicalSits within an extended incretin and glucagon signaling pathway, combining appetite-regulating incretin activity with glucagon-mediated energy expenditure signaling.
Phase 2 study used 24-week primary endpoint and 48-week secondary endpoint2
Research Phase 2
Growth Hormone Axis
Research focus
These peptides are studied for growth hormone signaling, IGF-1 response, body composition, and recovery-related research.
Studied Compounds
Tesamorelin
Strong within approved contextOperates within the GH/IGF-1 axis at the hypothalamic-pituitary signaling layer, upstream of systemic IGF-1 effects.
Clinical studies measured visceral adipose tissue changes at 26 weeks, with extension data to 52 weeksSermorelin
Moderate for acute endocrine responseSits within the hypothalamic-pituitary GH axis at the GHRH receptor signaling layer.
Days to weeks for hormonal endpointsCJC-1295
Low to moderate (pharmacodynamic only)Sits within the GH/IGF-1 axis at the GHRH receptor signaling layer, with extended pharmacokinetic profile.
Days to weeks for pharmacodynamic studiesIpamorelin
Low (acute hormonal only)Sits within the ghrelin/GH-axis signaling pathway, parallel to GHRH-driven pathways.
Acute studies; limited long-term outcome data3
Research Phase 3
Fat Metabolism Research
Research focus
AOD-9604 is studied for lipid metabolism and fat oxidation pathways.
Mechanism Flow
How signaling unfolds across the three research phases.
Phase 1 covers the initial biological process. Phase 2 maps the signaling cascades downstream. Phase 3 describes systemic effects studied in research models.
1
Phase 1 · Appetite and glucose signaling
- GLP-1, GIP, and glucagon receptor agonism
- Central appetite regulation via hypothalamic circuits
- Glycemic control and insulin response research
2
Phase 2 · GH-axis modulation
- GHRH analog and ghrelin-receptor agonist signaling
- Pulsatile growth hormone and IGF-1 response
- Body composition outcomes in clinical and preclinical research
3
Phase 3 · Lipid metabolism
- Fragment-based research on the lipolytic region of human GH
- Fat oxidation pathway studies
- Adipose tissue signaling models
Studied Compounds
Compounds studied within this pathway.
Each entry summarizes the mechanism explored in research literature. Not a recommendation, dosing guide, or protocol.
- SemaglutideStrong
Studied for GLP-1 receptor activation, delayed gastric emptying, and appetite signaling.
- TirzepatideStrong
Studied for GIP and GLP-1 receptor co-activation.
- RetatrutideEmerging
Studied for triple incretin/glucagon receptor activation.
- TesamorelinStrong
Studied for GHRH receptor activation and pulsatile GH release.
- SermorelinModerate
Studied for GHRH receptor activation and physiologic GH pulses.
- CJC-1295Low
Studied for sustained GHRH receptor activation.
- IpamorelinLow
Studied for selective GHS-R activation with limited cortisol/prolactin effect.
- AOD-9604Low
Studied for lipolytic signaling without GH-like growth effects.
Research Observation Timeline Across This Pathway
Timeline patterns measured in studies of these compounds.
Every compound in this pathway has a primary study window described in the research literature. Windows below describe research observation periods only — not expected personal outcomes.
Strong clinical · 2Emerging clinical · 1Strong within approved context · 1Moderate for acute endocrine response · 1Low to moderate (pharmacodynamic only) · 1Low (acute hormonal only) · 1Low / mixed for human outcomes · 1
- SemaglutideStrong clinical
Measured in studies: Major clinical trials measured body-weight and metabolic outcomes at 68 weeks
Endpoint type · Clinical outcome endpoints (glycemic, body weight, cardiovascular)
- TirzepatideStrong clinical
Measured in studies: Major clinical trials measured outcomes at 72 weeks
Endpoint type · Clinical outcome endpoints (glycemic and body weight)
- RetatrutideEmerging clinical
Measured in studies: Phase 2 study used 24-week primary endpoint and 48-week secondary endpoint
Endpoint type · Clinical outcome endpoints (body weight, glycemic, hepatic)
- TesamorelinStrong within approved context
Measured in studies: Clinical studies measured visceral adipose tissue changes at 26 weeks, with extension data to 52 weeks
Endpoint type · Imaging and biomarker endpoints
- SermorelinModerate for acute endocrine response
Measured in studies: Days to weeks for hormonal endpoints
Endpoint type · Hormonal biomarker endpoints
- CJC-1295Low to moderate (pharmacodynamic only)
Measured in studies: Days to weeks for pharmacodynamic studies
Endpoint type · Pharmacodynamic hormone endpoints
- IpamorelinLow (acute hormonal only)
Measured in studies: Acute studies; limited long-term outcome data
Endpoint type · Hormonal biomarker endpoints
- AOD-9604Low / mixed for human outcomes
Measured in studies: Preclinical studies often used short windows (e.g. 14 days in obese mice)
Endpoint type · Biomarker and adipose tissue endpoints
These windows reflect research observation periods only, not guaranteed personal outcomes.
Research Insights
What current research focuses on.
- Incretin-based compounds (semaglutide, tirzepatide) are supported by large-scale human clinical trial data.
- GHRH/ghrelin-receptor compounds have human data but more variable outcome studies.
- AOD-9604 and other GH-fragment research is largely preclinical with weaker clinical signals.
Research Limitations
Where the evidence base is incomplete.
- Long-term outcome data varies considerably between approved drugs and research-only compounds.
- Off-label and research use settings introduce significant variability not captured in trials.
- Effects on body composition do not translate uniformly across populations or contexts.
Transparency note · evidence gaps disclosed for research integrity
Research Relationship Overview
How these compounds are studied together.
Each phase groups compounds with mechanistic overlap. The diagram shows which compounds are explored in combination within published research literature — not a recommended use strategy.
Pathway hubResearch phaseStudied compoundMechanistic overlap
DisclaimerThis visualization reflects research relationships and does not represent a recommended use strategy. Compounds shown here are studied together in research contexts only — this is not a protocol, dosing guide, or medical advice.
Catalog · Research compounds
Related Compounds Available
Compounds referenced in this pathway's research literature. Each links to its full Library profile — mechanism, evidence, and research context. Research use only.
Strong
Tirzepatide
Dual GIP/GLP-1 agonist studied in metabolic research.
Category · Fat LossMech 10/10
View ProductRetatrutide
Triple agonist (GLP-1, GIP, glucagon) studied in metabolic trials.
Category · Fat LossMech 9/10
View ProductTesamorelin
GHRH analog studied for visceral adiposity research.
Category · Growth Hormone AxisMech 9/10
View ProductSermorelin
GHRH analog studied for endogenous GH signaling.
Category · Growth Hormone AxisMech 8/10
View ProductCJC-1295
Long-acting GHRH analog studied in GH signaling research.
Category · Growth Hormone AxisMech 7/10
View ProductIpamorelin
Selective GH secretagogue studied for ghrelin receptor signaling.
Category · Growth Hormone AxisMech 7/10
View ProductAOD-9604
Fragment of hGH (176-191) studied in lipid metabolism research.
Category · Fat LossMech 5/10
View ProductFor research use only · Not for human consumption
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.